Log In
BCIQ
Print this Print this
 

SER-109

  Manage Alerts
Collapse Summary General Information
Company Seres Therapeutics Inc.
DescriptionPurified and encapsulated suspension of about 50 species of Firmicute eubacterial spores derived from healthy donors' fecal matter
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic
Latest Stage of DevelopmentPhase II
Standard IndicationClostridium
Indication DetailsPrevent recurrent Clostridium difficile infection (CDI); Treat recurrent Clostridium difficile infection (CDI)
Regulatory Designation U.S. - Breakthrough Therapy (Prevent recurrent Clostridium difficile infection (CDI));
U.S. - Orphan Drug (Prevent recurrent Clostridium difficile infection (CDI))
PartnerNestle S.A.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,880.0M

$120.0M

$1,760.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/11/2016

$1,880.0M

$120.0M

$1,760.0M

Get a free BioCentury trial today